von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease

Summary

Background. Elevated von Willebrand factor (vWF) is a risk factor in the development of acute myocardial infarction. The importance of vWF and factor VIII :C in the pathogenesis of cerebrovascular disease (CVD) is poorly defined.

Methods and results. We studied 208 cases of stroke whose pathological type was defined by cranial computed tomography. Cerebral infarcts were grouped according to the Oxfordshire Community Stroke Project (OCSP) clinical classification. The results in patients were compared with 184 healthy reference subjects. In patients, vWF and FVIII: C levels were determined initially and after three months. Patients were followed prospectively for six months or until death.

Levels of vWF and FVIII :C were elevated initially (1.86 IU/ml and 2.20 U/ml respectively) and after 3 months (1.51 IU/ml and 1.90 U/ml) compared with a healthy reference population (1.26 IU/ml and 1.49 U/ml p = 0.0001). In the initial sample, vWF was associated with age (p = 0.01). FVIII: C was related to age (p = 0.04), gender (p = 0.007 higher for females) and a history of diabetes mellitus (2.56 U/ml vs. 2.16 U/ml in non-diabetics, p = 0.008).

Initial vWF levels were higher in subjects with large vessel disease (TACI/PACI) group compared with the small vessel disease (LACI) group [2.12 IU/ml, (n = 112) vs. 1.48 IU/ml (n = 59) respectively, p = 0.0001] and similarly in initial FVIII :C levels (2.43 U/ml vs. 1.87 U/ml, p = 0.0001).

Analysis of six-month case fatality, vWF levels were associated with risk of death [p = 0.01, OR 1.73 (1.12,2.66) for an increase of 1 U/ml], even after allowing for stroke type.

Conclusion. The relationship of vWF with stroke mortality has not previously been described. Although we have not demonstrated a causal role for vWF in the pathogenesis of CVD, elevated circulating levels of vWF may be associated with increased risk of death following stroke. A prospective study would be required to establish whether vWF is predictive for the development of CVD.

• References

• 1 Lollar P. The association of factor VIII with von Willebrand factor. Mayo Clin Proc 1991; 66: 524-534
• 2 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155
• 3 Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den OttolanderGJH. Albuminuria, cardiovascular disease and endothelial cell dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323
• 4 Sugrue DD, Trayner I, Thompson GR, Vere VJ, Dimeson J, Stirling Y, Meade TW. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985; 53: 265-268
• 5 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 6 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de LooJC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641
• 7 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355
• 8 Hantano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541-553
• 9 Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Preventive and Social Medicine 1977; 31: 42-48
• 10 Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526
• 11 Hart RG, Kanter MC. Haematologic disorders and ischaemic stroke. Stroke 1990; 21: 1111-1121
• 12 Mettinger KL. A study of haemostasis in ischaemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin. Thromb Res 1982; 26: 183-192
• 13 Landi G, D’Angelo A, Boccardi E, Candelise L, Mannucci PM, Nobile OrazioE, Morabito A. Hypercoagulability in acute stroke: prognostic significance. Neurology 1987; 37: 1667-1671
• 14 Kosik KS, Furie B. Thrombotic stroke associated with elevated plasma factor VIII. Ann Neurol 1980; 8: 435-437
• 15 Marra R, De Stefano V, Pagano L, Giovannini G, Bizzi B. Evaluation of some coagulation parameters in cerebral ischaemia. Acta Neurol Scand 1983; 67: 210-217
• 16 Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Thromb Haemost 1995; 73: 561-567
• 17 Mannucci PM, Ruggeri ZM, Gagnatelli G. Nervous regulation of Factor VIII levels in man. Br J Haematol 1971; 20: 195-207
• 18 Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. JAMA 1983; 250: 2942-2946
• 19 Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost 1993; 70: 111-118
• 20 Ip JH, Fuster V, Badimon L, Taubman M, Badimon J, Chesebro JH. Syndromes of accelerated atherosclersosis. Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687
• 21 Dennis MS, Burn JPS, Sandercock PA, Bamford J, Wade DT, Warlow CP. Long term survival after first-ever stroke: The Oxfordshire Community Stroke Project. Stroke 1993; 24: 796-800
• 22 Haines AP, Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Craig MWM. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983; 50: 800-803